氟哌卩塞吨美利曲辛和氟西汀治疗功能性胃肠病的疗效比较李正兴蒋国强(四川省中江县人民医院呼吸科618100)【摘要】目的比较氟哌曝吨美利曲辛和氟西汀治疗功能性胃肠病(FGID)的疗效，同时探寻抗焦虑抗抑郁药在治疗功能性胃肠病(FGID)的作用和地位。方法根据“罗马III标准”确诊功能性胃肠病(FGID)⑴撚后选取其中300名患者，利用单纯随机分组的方式分为四组每组100人。第一组接受氟哌曝吨美利曲辛，第二组接受氟西汀治疗，第三组为对照组，只接受心理辅导不接受抗抑郁抗焦虑药物治疗，同时各组患者根据具体症状和病情需要给予莫沙必利、曲美布丁、奥美拉哇、硫糖铝或铝碳酸镁等常规对症治疗治疗。然后在各组患者完成8周的疗程后评测其治疗前后消化道症状和焦虑、抑郁自评量表积分变化⑵，依据各组评分结果评价各组疗效。结果氟哌曝吨美利曲辛和氟西汀组的消化道症状有效率分别为81%和80%,均显著高于常规疗法的32%(PV0.001);氟哌曝吨美利曲辛和氟西汀组功能性胃肠病(FGID)原有精神异常患者和无精神异常患者的消化道症状有效率分别为80%和79%,差异无统计学意义(P>0.05);氟哌嘍吨美利曲辛和氟西汀组治疗前后焦虑自评量表(SAS)总分差值比较无统计学意义(P>0.05),抑郁自评量表(SDS)总分差值比较则氟西汀组优于氟哌陵吨美利曲辛组(P<0.001)o结论氟哌曝吨美利曲辛和氟西汀对于改善功能性胃肠病(FGID)的消化道症状I•分有效。同时,疗效与症状类别有关，但是与目前是否存在精神异常无关。【关键词】］氟哌卩塞吨美利曲辛氟西汀功能性胃肠病【中图分类号】R453【文献标识码】A【文章编号】2095-1752(2014)24-0018-03FlupentixolandmelitracentabletsandfluoxetineinthetreatmentoffunctionalgastrointestinaldiseasecurativeeffectcomparisonLiZhengxingJiangGuoqiangDepartmentofRespiratory,TheZhongjiangPeople'sHospital,SichuanProvinee,618100,China【Abstract]ObjectiveTocomparethetherapeuticeffectofFlupentixolandmelitracentabletsandfluoxetineinthetreatmentoffunctionalgastrointestinaldisorders(FGID)andtoexplore,andtheroleofstatusofantianxietyandantidepressantinthetreatmentoffunctionalgastrointestinaldisorders(FGID).MethodAccordingtotheHRomeIIIstandardHdiagnosisoffunctionalgastrointestinaldisorders(FGID),andthenselected300patients,usingsimplerandomdividedintofourgroupsof100people.Thefirstgroupreceivedflupenthixolandmelitracen,thesecondgroupreceivedfluoxetineinthetreatmentgroup,thirdforthecontrolgroup,onlytoreceivepsychologicalcounselingdoesnotaccepttheantidepressantandanxiolyticdrugtherapy,whilepatientsineachgroupaccordingtothespec讦icsymptomsanddiseaseneedtobegivenmosapride,CuMeiBoudin,Ogilvypullthiazole,sucralfateorhydrotalciteandotherconventionalsymptomatictreatmenttreatment.Thencompleted8weeksoftreatmentineachgroupofpatientsafterevaluationbeforeandafterthetreatmentofgastrointestinalsymptomsandanxiety,selfratingDepressionScalescoreswerebasedontheresults,eachscoreevaluationthecurativeeffectofeachgroup.ResultsFlupentixolandmelitracentabletsandfluoxetinegroupofdigestivetractsymptomswereimprovedin81%and80%,weresignificantlyhigherthanthatofconventionaltherapy,32%(P<0.001);Flupentixolandmelitracentabletsandfluoxetinegroupfunctionalgastrointestinaldisease(FGID)patientswithabnormaloriginalspiritofpatientswithandwithoutabnormalspiritgastrointestinalsymptomswereimprovedin80%and79%,nosign讦icantdifference(P>0.05);andFlupentixolandmelitracentabletsandfluoxetineintreatmentofselfratingAnxietyScale(SAS)scorediffereneewasnotstatisticallysignificant(P>0.05),selfratingDepressionScale(SDS)scoredifferencebetweenfluoxetinegroupisbetterthancomparisonFlupentixolandmelitracengroup(P<0.001).ConelusionFlupentixolandmelitracentabletsandfluoxet...